Events Archives - Page 16 of 128

1 minute read

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data For MB-106 At The 2023 ASH Annual Meeting

December 11, 9:37 AM

Data showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma100% of patients with follicular

MBIO

1 minute read

Events
News

TScan Therapeutics on Saturday Presented Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

By Charles Gross

December 11, 8:39 AM

TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today

TCRX

1 minute read

Events
News

Centessa Pharmaceuticals Announced New Data From Additional 52-Weeks of Continuous Treatment From Third Year (Part 5) Of Ongoing Phase 2a Study Of SerpinPC For Treatment Of Hemophilia At 2023 ASH Meeting

By Charles Gross

December 10, 1:57 PM

Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of

CNTA

1 minute read

Events
News

Molecular Partners Presented Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial Of MP0533 For Patients With Relapsed/Refractory AML And AML/MDS At 2023 ASH Meeting

By Charles Gross

December 10, 1:51 PM

Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today presented positive initial clinical data from its

MOLN

1 minute read

Events
News

Bristol Myers Squibb On Saturday Presented Primary Efficacy, Safety Analysis of the Phase 3 COMMANDS Trial Of Reblozyl For Treatment Of Anemia In Erythropoiesis Stimulating Agent-Naïve Patients With Lower-Risk Myelodysplastic Syndromes At 2023 ASH Meet…

By Charles Gross

December 10, 11:15 AM

Bristol Myers Squibb (NYSE:BMY) announced updated results from the primary analysis of the Phase 3 COMMANDS trial, comparing Reblozyl® (luspatercept-aamt) versus epoetin alfa for the treatment of anemia in

BMY

1 minute read

Events
News

Biomea Fusion Announced Saturday Near Doubling The Percentage Of Patients With Durable HbA1c Reduction In the 200 mg Dose Cohorts

By Charles Gross

December 10, 11:08 AM

Biomea Fusion, Inc. (“Biomea”) (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with

BMEA

1 minute read

Events
News

Aptose Tuspetinib Clinical Data Featured In Oral Presentation Saturday At 2023 ASH Meeting; Said TUS/VEN Combination Active Across Broad Populations Of AML And Demonstrates 25% Complete Response Rate Among All-comers, Including 20% CRc In Wildtype AML

By Charles Gross

December 10, 9:14 AM

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic

APTO

1 minute read

Events
News

Pfizer Announced Saturday Marstacimab Phase 3 Data Presented At ASH 2023 Demonstrate Significant Bleed Reduction In Hemophilia A And B

By Charles Gross

December 10, 8:34 AM

Pfizer Inc. (NYSE:PFE) presented results from the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab for the treatment of people with severe hemophilia A and moderately severe to severe hemophilia

PFE

2 minute read

Events
News

Autolus Therapeutics Presented Clinical Data Updates Saturday At 2023 ASH Meeting

By Charles Gross

December 10, 8:32 AM

Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces two oral presentations and two poster presentations at the

AUTL

1 minute read

Events
News

Cogent Biosciences Announced Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib In Patients with Nonadvanced Systemic Mastocytosis 57% Median Best Improvement On MC-QoL And 78% Of Patients Reporting ≥1 Point Improvement On PGIS By Week 20

By Charles Gross

December 9, 4:16 PM

Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported positive initial data from the Company’s ongoing Phase

COGT